A new treatment for Multiple Sclerosis not only stops the disease from advancing but may help patients recover from disability.
Remarkable results for the drug alemtuzumab mean it has been approved for use on the NHS and is now available in England.
Originally a pioneering cancer therapy, Cambridge University scientists have spent almost 25 years developing it as a treatment for MS sufferers.
Trials involving more than 1,500 patients show treatment led to fewer relapses compared with multiple jabs of the treatment beta interferon each week, cutting further disability and even allowing some existing damage to recover.
So 1 in 10 Brits voted UKIP last week?
Seems like the media can’t stop drivelling on about it. And people can’t stop drivelling about the media coverage.
Yet – amidst all the tumult and the shouting – here is one fact the media have missed reporting . As they have, consistently, for years and years and years.
There’s another one in 10 people in the UK who nobody mentions – the one in 10 who are unpaid family carers. On duty – responsible for someone’s life – many for the full 168 hours a week, week in, week out. It is quite as dreadful as it sounds. You have difficulty with everything: working, sleeping, socialising, existing. Paying bills. Getting out. You don’t tend to get luxuries like bank holidays. And, no, you don’t get used to it.
A new mobile app and website designed to help patients better manage their medicines and thus boost treatment adherence has been launched in the UK by Janssen Healthcare Innovation (JHI).
Care4Today Mobile Health Manager triggers medication dosing and repeat prescription reminders and also gives family members and carers the opportunity to provide support through a digital network.
